Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diamondback Energy Inc (FANG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Diamondback Energy IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Diamondback Energy Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Diamondback Energy Inc trades at $201.07 (market cap $56.48B), while Regeneron Pharmaceuticals Inc trades at $796.21 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Diamondback Energy Inc pays the higher dividend (2.18%). Which is the better fit depends on your goals.

FANGREGN
Market Cap
$56.48B$82.06B
Sector
EnergyHealth
52-Week High
$213.69$812.27
52-Week Low
$134.53$555.51
Enterprise Value
$68.63B$76.77B
Dividend Yield
2.18%0.47%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diamondback Energy Inc

Diamondback Energy (FANG) trades at $198.97, up 5.81% with strong Q2 2026 earnings beating estimates. Technical indicators show bullish momentum with support at $193 and resistance at $202. Revenue grew to $14.93B in 2025, though profit margins compressed to 11.14%. Analyst consensus is strongly bullish with a $236.63 price target and 90% buy ratings.

FANG offers growth potential through production increases and debt reduction, supported by elevated oil prices. Risks include commodity price volatility and margin pressure from rising costs. The stock trades at a premium P/E of 38.42 but remains attractive given operational efficiency gains and institutional accumulation.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $808.05, up 3.02% today, with strong technical momentum and bullish moving averages. The company shows robust fundamentals: Q2 2026 EPS of $14.29 beat expectations by over 40%, revenue grew to $14.34B in 2025, and profit margins exceed 27%. However, RSI levels above 95 indicate overbought conditions, and the stock faces headwinds from multiple class-action lawsuits related to clinical trial disclosures.

Outlook remains positive due to earnings beats and product strength in Eylea HD and Dupixent, but legal overhangs and high valuation multiples pose near-term risks. Analysts maintain a Buy consensus with a $756.93 price target, suggesting cautious optimism amid legal scrutiny.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Diamondback Energy Inc

Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.

Read more on FANG

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN